Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sipuleucel-T +/- Radium-223 in mCRPC
NCT02463799Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2016
- Primary completion
- Dec 2019
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Feb 2016; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02463799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02463799.